292 related articles for article (PubMed ID: 35386270)
1. Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers.
Choi E; Buie J; Camacho J; Sharma P; de Riese WTW
Res Rep Urol; 2022; 14():87-108. PubMed ID: 35386270
[TBL] [Abstract][Full Text] [Related]
2. Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.
Ali Shah SI
South Asian J Cancer; 2015; 4(2):95-7. PubMed ID: 25992351
[TBL] [Abstract][Full Text] [Related]
3. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
4. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.
Schulman C; Irani J; Aapro M
BJU Int; 2012 Jun; 109 Suppl 6():13-21. PubMed ID: 22672121
[TBL] [Abstract][Full Text] [Related]
5. Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.
Phillips I; Shah SI; Duong T; Abel P; Langley RE
Oncol Hematol Rev; 2014; 10(1):42-47. PubMed ID: 24932461
[TBL] [Abstract][Full Text] [Related]
6. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
Sathianathen NJ; Koschel S; Thangasamy IA; Teh J; Alghazo O; Butcher G; Howard H; Kapoor J; Lawrentschuk N; Siva S; Azad A; Tran B; Bolton D; Murphy DG
Eur Urol; 2020 Mar; 77(3):365-372. PubMed ID: 31679970
[TBL] [Abstract][Full Text] [Related]
7. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand.
Wang A; Obertová Z; Brown C; Karunasinghe N; Bishop K; Ferguson L; Lawrenson R
BMC Cancer; 2015 Nov; 15():837. PubMed ID: 26525985
[TBL] [Abstract][Full Text] [Related]
8. The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer.
Gunner C; Gulamhusein A; Rosario DJ
J Clin Urol; 2016 Dec; 9(2 Suppl):24-29. PubMed ID: 28344813
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
10. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
11. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
12. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes.
Ahmadi H; Daneshmand S
Patient Relat Outcome Meas; 2014; 5():63-70. PubMed ID: 25045284
[TBL] [Abstract][Full Text] [Related]
15. Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture.
Wilson HC; Shah SI; Abel PD; Price P; Honeyfield L; Edwards S; Abel RL
Cent European J Urol; 2015; 68(2):165-8. PubMed ID: 26251735
[TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy for prostate cancer.
Sharifi N; Gulley JL; Dahut WL
JAMA; 2005 Jul; 294(2):238-44. PubMed ID: 16014598
[TBL] [Abstract][Full Text] [Related]
17. Steroid Hormone Biosynthesis Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate Cancer.
Feng LR; Barb JJ; Allen H; Regan J; Saligan L
Front Cell Dev Biol; 2021; 9():642307. PubMed ID: 34079794
[TBL] [Abstract][Full Text] [Related]
18. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
Mohamad NV; Soelaiman IN; Chin KY
Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.
Martín-Merino E; Johansson S; Morris T; García Rodríguez LA
Drug Saf; 2011 Nov; 34(11):1061-77. PubMed ID: 21981434
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]